Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells
Authors
Keywords
-
Journal
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
Volume 69, Issue 7, Pages 461-473
Publisher
SAGE Publications
Online
2021-06-15
DOI
10.1369/00221554211026297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2+ Breast Cancer Cells
- (2021) Silvia Marconi et al. Membranes
- Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
- (2020) Arlene Chan et al. Clinical Breast Cancer
- Endocytosis: a pivotal pathway for regulating metastasis
- (2020) Imran Khan et al. BRITISH JOURNAL OF CANCER
- Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance
- (2019) Selma Maacha et al. Molecular Cancer
- Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
- (2019) Collins et al. Cancers
- Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
- (2019) Paul Dent et al. ONCOGENE
- Not the comfy chair! Cancer drugs that act against multiple active sites
- (2019) Laurence Booth et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Life in the lumen: The multivesicular endosome
- (2019) Jean Gruenberg TRAFFIC
- Neratinib for the treatment of HER2-positive early stage breast cancer
- (2017) Isabel Echavarria et al. Expert Review of Anticancer Therapy
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles
- (2017) Vanesa G. Martinez et al. OncoImmunology
- Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells
- (2016) Patrizio Castagnola et al. Oncotarget
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Binding of Trastuzumab to ErbB2 Is Inhibited by a High Pericellular Density of Hyaluronan
- (2012) Tímea Váradi et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
- (2012) Katia Cortese et al. MOLECULAR BIOLOGY OF THE CELL
- Flotillins as regulators of ErbB2 levels in breast cancer
- (2012) S Pust et al. ONCOGENE
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells
- (2010) Mark T. Howes et al. JOURNAL OF CELL BIOLOGY
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More